Event Pulse: Launches of Xgeva and Provenge includes analysis of a targeted Internet survey of 50 oncologists and 50 urologists, 10 in-depth telephone interviews with pharmacy directors at major managed care organizations, and longitudinal treatment data from a panel of 450 oncologists spanning 2005-2011. Conducted in February to March 2011, the report provides an in-depth look at how the launches of Xgeva and Provenge will impact the treatment paradigm among competing agents in the prostate cancer market. The study also examines the reimbursement climate for existing and anticipated prostate cancer agents.About Event Pulse
ITG's Majestic Market Research Prostate Cancer Study Indicates Amgen's Xgeva Is Poised To Steal Significant Share From Novartis' Zometa; Physicians Still On The Fence About Dendreon's Provenge
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.